HU216020B - Eljárás vCD44 sejtfelületi protein elleni antitesteket tartalmazó immunszuppresszív gyógyszerkészítmények előállítására, és ilyen antitesteket tartalmazó diagnosztikai készlet - Google Patents

Eljárás vCD44 sejtfelületi protein elleni antitesteket tartalmazó immunszuppresszív gyógyszerkészítmények előállítására, és ilyen antitesteket tartalmazó diagnosztikai készlet Download PDF

Info

Publication number
HU216020B
HU216020B HUP9203337A HU9203337A HU216020B HU 216020 B HU216020 B HU 216020B HU P9203337 A HUP9203337 A HU P9203337A HU 9203337 A HU9203337 A HU 9203337A HU 216020 B HU216020 B HU 216020B
Authority
HU
Hungary
Prior art keywords
vcd44
antibody
medicament
antibodies
cells
Prior art date
Application number
HUP9203337A
Other languages
English (en)
Hungarian (hu)
Other versions
HUT63063A (en
Inventor
Peter Herrlich
Helmut Ponta
Margot Zöller
Original Assignee
Boehringer Ingelheim International Gmbh.
Deutsches Krebsforschungszentrum
Forschungszentrum Karlsruhe Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh., Deutsches Krebsforschungszentrum, Forschungszentrum Karlsruhe Gmbh filed Critical Boehringer Ingelheim International Gmbh.
Publication of HUT63063A publication Critical patent/HUT63063A/hu
Publication of HU216020B publication Critical patent/HU216020B/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUP9203337A 1991-10-23 1992-10-22 Eljárás vCD44 sejtfelületi protein elleni antitesteket tartalmazó immunszuppresszív gyógyszerkészítmények előállítására, és ilyen antitesteket tartalmazó diagnosztikai készlet HU216020B (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4134982A DE4134982A1 (de) 1991-10-23 1991-10-23 Verwendung von antikoerper enthaltenden praeparationen zur immunsuppression

Publications (2)

Publication Number Publication Date
HUT63063A HUT63063A (en) 1993-07-28
HU216020B true HU216020B (hu) 1999-04-28

Family

ID=6443260

Family Applications (1)

Application Number Title Priority Date Filing Date
HUP9203337A HU216020B (hu) 1991-10-23 1992-10-22 Eljárás vCD44 sejtfelületi protein elleni antitesteket tartalmazó immunszuppresszív gyógyszerkészítmények előállítására, és ilyen antitesteket tartalmazó diagnosztikai készlet

Country Status (17)

Country Link
US (1) US5951982A (en:Method)
EP (1) EP0538754B1 (en:Method)
JP (1) JPH05310596A (en:Method)
KR (1) KR100252620B1 (en:Method)
AT (1) ATE162079T1 (en:Method)
AU (1) AU659687B2 (en:Method)
CA (1) CA2081150C (en:Method)
DE (2) DE4134982A1 (en:Method)
DK (1) DK0538754T3 (en:Method)
ES (1) ES2111031T3 (en:Method)
GR (1) GR3026526T3 (en:Method)
HU (1) HU216020B (en:Method)
IL (1) IL103510A0 (en:Method)
NO (1) NO311965B1 (en:Method)
NZ (1) NZ244851A (en:Method)
TW (1) TW273514B (en:Method)
ZA (1) ZA928162B (en:Method)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589458A (en) * 1992-11-13 1996-12-31 Thomas Jefferson University Compounds that inhibit T cell proliferation and methods for using the same
EP0703989B1 (en) * 1993-06-18 1997-11-05 Oy Biotie Therapies COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CD44v6
DE4326573A1 (de) * 1993-08-07 1995-02-23 Boehringer Ingelheim Int Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren
DE4431297A1 (de) * 1994-09-02 1996-03-07 Boehringer Ingelheim Int Monoklonaler Antikörper gegen CD44v6
DE19540515C1 (de) * 1995-10-31 1997-02-06 Boehringer Ingelheim Int Tumortherapie durch adoptiven Transfer CD44v-spezifischer zytotoxischer T-Lymphozyten
WO1997030173A1 (fr) * 1996-02-15 1997-08-21 Chugai Seiyaku Kabushiki Kaisha Anticorps monoclonal reconnaissant les antigenes presents a la surface des cellules endotheliales d'un vaisseau tumoral
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
DE19652815C2 (de) * 1996-12-18 1999-11-11 Karlsruhe Forschzent Mittel zur Identifizierung und Therapie metastasierender Tumore
DE19653607A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen
DE19708713C2 (de) * 1997-03-04 2002-11-28 Boehringer Ingelheim Int Verwendung von anti-CD44 Antikörpern enthaltenden Präparationen zur Behandlung bestimmter Tumore und zur Unterdrückung von Immunreaktionen
IL121656A0 (en) * 1997-08-29 1998-02-08 Yissum Res Dev Co Diagnosis prevention and treatment of diabetes
US7534605B2 (en) 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
AU2003272511A1 (en) * 2002-09-13 2004-04-30 Dyax Corporation Cd44-binding ligands
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
WO2005087264A1 (en) * 2004-03-17 2005-09-22 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Cd44-targeting for reducing/preventing ischemia-reperfusion-injury
WO2007025166A2 (en) 2005-08-25 2007-03-01 Repair Technologies, Inc. Devices, compositions and methods for the protection and repair of cells and tissues
JP2009531324A (ja) 2006-03-20 2009-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌標的化のための操作された抗前立腺幹細胞抗原（ｐｓｃａ）抗体
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
WO2010058396A1 (en) 2008-11-19 2010-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A cd44vra antibody and diagnostic and therapeutic methods using same
US10517969B2 (en) 2009-02-17 2019-12-31 Cornell University Methods and kits for diagnosis of cancer and prediction of therapeutic value
CN102753194B (zh) 2009-12-02 2015-07-08 伊麦吉纳博公司 靶向人前列腺特异性膜抗原的j591微抗体和双抗体
DK2886126T3 (en) 2013-12-23 2017-09-18 Exchange Imaging Tech Gmbh Nanoparticle conjugated to CD44-binding peptides
HUE049261T2 (hu) 2014-07-15 2020-09-28 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd CD44 izolált polipeptidek és alkalmazásaik
KR102749049B1 (ko) 2015-08-07 2025-01-02 이미지냅 인코포레이티드 분자를 표적화하기 위한 항원 결합 구조체
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
US11313243B2 (en) 2018-07-12 2022-04-26 Rolls-Royce North American Technologies, Inc. Non-continuous abradable coatings

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3852236T2 (de) * 1987-08-11 1995-04-06 Univ Leland Stanford Junior Verfahren zur Kontrolle der Leukozyten-Extravasation.
DE4014510A1 (de) * 1990-05-07 1991-11-14 Kernforschungsz Karlsruhe Variante cd44-oberflaechenproteine, diese kodierende c-dna-sequenzen, antikoerper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie
CA2059824A1 (en) * 1991-02-26 1992-08-27 Thomas M. Aune Hybridomas and monoclonal antibodies that inhibit anti-cd3-stimulated t cell proliferation
EP0703989B1 (en) * 1993-06-18 1997-11-05 Oy Biotie Therapies COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CD44v6

Also Published As

Publication number Publication date
HUT63063A (en) 1993-07-28
IL103510A0 (en) 1993-03-15
AU2724492A (en) 1993-04-29
ES2111031T3 (es) 1998-03-01
GR3026526T3 (en) 1998-07-31
AU659687B2 (en) 1995-05-25
CA2081150A1 (en) 1993-04-24
NZ244851A (en) 1997-07-27
EP0538754A3 (en) 1994-05-25
TW273514B (en:Method) 1996-04-01
NO924103D0 (no) 1992-10-22
ZA928162B (en) 1993-05-05
EP0538754B1 (de) 1998-01-14
EP0538754A2 (de) 1993-04-28
JPH05310596A (ja) 1993-11-22
ATE162079T1 (de) 1998-01-15
US5951982A (en) 1999-09-14
KR930007460A (ko) 1993-05-20
DK0538754T3 (da) 1998-03-30
KR100252620B1 (ko) 2000-09-01
NO311965B1 (no) 2002-02-25
DE4134982A1 (de) 1993-04-29
NO924103L (no) 1993-04-26
DE59209129D1 (de) 1998-02-19
CA2081150C (en) 2001-04-10

Similar Documents

Publication Publication Date Title
HU216020B (hu) Eljárás vCD44 sejtfelületi protein elleni antitesteket tartalmazó immunszuppresszív gyógyszerkészítmények előállítására, és ilyen antitesteket tartalmazó diagnosztikai készlet
Sakaguchi et al. B lymphocyte lineage‐restricted expression of mb‐1, a gene with CD3‐like structural properties.
JP4113929B2 (ja) アンチｃｄ６モノクロナール抗体とその利用
AU701105B2 (en) Colon cell and colon cancer cell associated nucleic acid molecules, protein and peptides
EP0766745A1 (en) Monoclonal antibody specific for human 4-1bb and cell line producing same
AU4032299A (en) Fap alpha-specific antibody with improved producibility
JP2002518347A (ja) 前立腺癌治療のための免疫療法組成物および方法
EP0977856A1 (en) Lag-3 splice variants
EP1721978B1 (fr) Séquences nucléotidiques codant pour des régions variables de chaines alpha des récepteurs des lymphocytes humains ainsi que leurs applications
ES2211877T3 (es) Linea celular linfoblastoide b humana que secreta un anticuerpo anti-gangliosido.
CA2468888C (en) Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof
CN1259972C (zh) 抗凝剂和人源化抗冯·维勒布兰德氏因子的单克隆抗体
JP2013177395A (ja) 哺乳動物を治療して体重減少又は肥満の減少を生じさせる方法
KR20080105111A (ko) 항 ＥｐｈＡ４ 항체의 효과기 기능을 이용한 세포 손상 방법
EP4198051A1 (en) Fusion protein comprising il-12 and anti-fap antibody, and use thereof
ES2619313T3 (es) Terapia de anticuerpos monoclonales para el cáncer de páncreas
JP2001507219A (ja) 単離された哺乳動物単球細胞遺伝子；関連する試薬
HUT55412A (en) Process for producing new glycoprotein and the gen coding them
Reiser et al. Cloning and expression of a cDNA for the T-cell-activating protein TAP.
EP4588941A1 (en) Nkg2d-nkp46 cell adapter molecule and use thereof
JP2003529370A (ja) 血管浸透性に対する有害な作用を有さないｖｅ−カドヘリンに対する拮抗薬抗体
EP0368920B1 (fr) Lectines fixant le beta-d-galactoside
KR100204733B1 (ko) 인체 4-1비비 분자에 특이성이 있고 면역억제 효과를 갖는 모노클로날 항체
JPH11310537A (ja) 温熱療法及び薬剤
US5719268A (en) Endothelial cell adhesion molecules

Legal Events

Date Code Title Description
HMM4 Cancellation of final prot. due to non-payment of fee